Skip to main content

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells

Journal of Neuro-Oncology volume 132, pages 219–229 (2017)Cite this article

Abstract

Protein kinase CK2 is a ubiquitously expressed serine/threonine kinase composed of two catalytic subunits (α) and/or (α′) and two regulatory (β) subunits. The expression and kinase activity of CK2 is elevated in many different cancers, including glioblastoma (GBM). Brain tumor initiating cells (BTICs) are a subset of cells that are highly tumorigenic and promote the resistance of GBM to current therapies. We previously reported that CK2 activity promotes prosurvival signaling in GBM. In this study, the role of CK2 signaling in BTIC function was examined. We found that expression of CK2α was increased in CD133+ BTICs compared to CD133− cells within the same GBM xenolines. Treatment with CX-4945, an ATP-competitive inhibitor of CK2, led to reduced expression of Sox2 and Nestin, transcription factors important for the maintenance of stem cells. Similarly, inhibition of CK2 also reduced the frequency of CD133+ BTICs over the course of 7 days, indicating a role for CK2 in BTIC persistence and survival. Importantly, using an in vitro limiting dilution assay, we found that inhibition of CK2 kinase activity with CX-4945 or siRNA knockdown of the CK2 catalytic subunits reduced neurosphere formation in GBM xenolines of different molecular subtypes. Lastly, we found that inhibition of CK2 led to decreased EGFR levels in some xenolines, and combination treatment with CX-4945 and Gefitinib to inhibit CK2 and EGFR, respectively, provided optimal inhibition of viability of cells. Therefore, due to the integration of CK2 in multiple signaling pathways important for BTIC survival, CK2 is a promising target in GBM.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507

    CAS  Article  Google Scholar 

  2. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842–1850

    CAS  Article  Google Scholar 

  3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O′Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110

    CAS  Article  Google Scholar 

  4. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Noushmehr H, Iavarone A, Verhaak RG (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3):550–563

    CAS  Article  Google Scholar 

  5. Altaner C (2008) Glioblastoma and stem cells. Neoplasma 55(5):369–374

    CAS  PubMed  Google Scholar 

  6. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 5:67–78

    Article  Google Scholar 

  7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760

    CAS  Article  Google Scholar 

  8. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828

    CAS  PubMed  Google Scholar 

  9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401

    CAS  Article  Google Scholar 

  10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14(1):123–129

    CAS  Article  Google Scholar 

  11. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31(5):857–869

    CAS  Article  Google Scholar 

  12. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369(1):1–15

    CAS  Article  Google Scholar 

  13. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, Cochet C, Issinger OG, Boldyreff B (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23(3):908–915

    CAS  Article  Google Scholar 

  14. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O′Brien C, Seldin DC (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28(1):131–139

    CAS  Article  Google Scholar 

  15. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E (2012) Inhibition of casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 3:e271

    CAS  Article  Google Scholar 

  16. Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN (2013) Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res 19(23):6484–6494

    CAS  Article  Google Scholar 

  17. Nitta RT, Gholamin S, Feroze AH, Agarwal M, Cheshier SH, Mitra SS, Li G (2015) Casein kinase 2alpha regulates glioblastoma brain tumor-initiating cell growth through the beta-catenin pathway. Oncogene 34(28):3688–3699

    CAS  Article  Google Scholar 

  18. Dubois N, Willems M, Nguyen-Khac MT, Kroonen J, Goffart N, Deprez M, Bours V, Robe PA (2016) Constitutive activation of casein kinase 2 in glioblastomas: absence of class restriction and broad therapeutic potential. Int J Oncol 48(6):2445–2452

    CAS  Article  Google Scholar 

  19. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O′Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70(24):10288–10298

    CAS  Article  Google Scholar 

  20. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN (2011) Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10(12):2384–2393

    CAS  Article  Google Scholar 

  21. Rietze RL, Reynolds BA (2006) Neural stem cell isolation and characterization. Methods Enzymol 419:3–23

    CAS  Article  Google Scholar 

  22. Maecker HT, Frey T, Nomura LE, Trotter J (2004) Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 62(2):169–173

    Article  Google Scholar 

  23. Meares GP, Liu Y, Rajbhandari R, Qin H, Nozell SE, Mobley JA, Corbett JA, Benveniste EN (2014) PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Mol Cell Biol 34(20):3911–3925

    Article  Google Scholar 

  24. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB (2013) Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 16(10):1373–1382

    CAS  Article  Google Scholar 

  25. Guerra B, Siemer S, Boldyreff B, Issinger OG (1999) Protein kinase CK2: evidence for a protein kinase CK2beta subunit fraction, devoid of the catalytic CK2alpha subunit, in mouse brain and testicles. FEBS Lett 462(3):353–357

    CAS  Article  Google Scholar 

  26. Buganim Y, Faddah DA, Cheng AW, Itskovich E, Markoulaki S, Ganz K, Klemm SL, van Oudenaarden A, Jaenisch R (2012) Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 150(6):1209–1222

    CAS  Article  Google Scholar 

  27. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25(9–10):1439–1451

    CAS  Article  Google Scholar 

  28. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1):40–48

    CAS  Article  Google Scholar 

  29. So KS, Kim CH, Rho JK, Kim SY, Choi YJ, Song JS, Kim WS, Choi CM, Chun YJ, Lee JC (2014) Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. PLoS ONE 9(12):e114000

    Article  Google Scholar 

  30. Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39(1):29–36

    CAS  Article  Google Scholar 

  31. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012–2024

    CAS  Article  Google Scholar 

  32. Petras M, Lajtos T, Friedlander E, Klekner A, Pintye E, Feuerstein BG, Szollosi J, Vereb G (2013) Molecular interactions of ErbB1 (EGFR) and integrin-beta1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol 15(8):1027–1040

    CAS  Article  Google Scholar 

  33. Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O′Brien SE, Lim JK, Ryckman DM, Anderes K, Rice WG, Drygin D (2012) Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 322(1):113–118

    CAS  Article  Google Scholar 

  34. Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang L, Au A, Stoppler HJ, Xu Z, Jablons DM, You L (2014) CK2a, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res 33(1):93

    PubMed  PubMed Central  Google Scholar 

  35. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L (2012) Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS ONE 7(6):e38996

    CAS  Article  Google Scholar 

  36. Tang AQ, Cao XC, Tian L, He L, Liu F (2015) Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3-derived sphere-forming cells. Mol Med Rep 11(3):2221–2226

    CAS  Article  Google Scholar 

  37. Liu J, Cao XC, Xiao Q, Quan MF (2015) Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2alpha. Mol Med Rep 11(1):665–669

    CAS  Article  Google Scholar 

  38. Cheong JW, Min YH, Eom JI, Kim SJ, Jeung HK, Kim JS (2010) Inhibition of CK2{alpha} and PI3K/Akt synergistically induces apoptosis of CD34 + CD38- leukaemia cells while sparing haematopoietic stem cells. Anticancer Res 30(11):4625–4634

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. G. Yancey Gillespie and Catherine Langford of the UAB Brain Tumor Animal Models Core Facility (NIH P20CA151129) for assistance, and acknowledge the use of the UAB Rheumatic Diseases Core Center-Comprehensive Flow Cytometry Core (P30 AR048311 and P30 A127667). This work was supported by NIH grants R01CA194414 and R01CA1585340 (E.N.B.), T32NS048039 (A.L.R.), T32AI007051 (S.A.G.), R01CA138517 (S.E.N.) and R01CA1515122 (A.B.H.). Additional funding is from American Brain Tumor Association Discovery Grant (B.C.M.), William E. Cash Jr. Memorial Fund in Neuro-Oncology Research (B.C.M. and S.E.N.), Career Transition Award from the National Multiple Sclerosis Society TA3050-A-1 (G.P.M.), UAB Comprehensive Cancer Center (S.E.N.) and the UAB Brain Tumor SPORE Career Development Award Program via P20CA151129 (A.B.H.).

Author information

Authors and Affiliations

  1. Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA

    Amber L. Rowse, Sara A. Gibson, Gordon P. Meares, Rajani Rajbhandari, Susan E. Nozell, Kory J. Dees, Anita B. Hjelmeland, Braden C. McFarland & Etty N. Benveniste

  2. Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd, MCLM 388, Birmingham, AL, 35294-0004, USA

    Braden C. McFarland

  3. Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, 510, 20th Street South, FOT 1220D, Birmingham, AL, 35294-3412, USA

    Etty N. Benveniste

Authors
  1. Amber L. Rowse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara A. Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon P. Meares
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajani Rajbhandari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan E. Nozell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kory J. Dees
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anita B. Hjelmeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Braden C. McFarland
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Etty N. Benveniste
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Braden C. McFarland or Etty N. Benveniste.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 113 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rowse, A.L., Gibson, S.A., Meares, G.P. et al. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells. J Neurooncol 132, 219–229 (2017). https://doi.org/10.1007/s11060-017-2378-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2378-z

Keywords

  • Glioblastoma
  • CK2
  • BTIC
  • CD133
  • EGFR